The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling
Abstract
With the increasing prevalence of cardiovascular diseases (CVD) worldwide, finding reliable and clinically relevant biomarkers to predict acute cardiovascular events has been a major aim of the scientific and medical community. Improvements of the understanding of the pathophysiological pathways of the disease highlighted the major role of lipoprotein particles, and these past decades have seen the emergence of a number of new methodologies to separate, measure and quantitate lipoproteins. Those methods, also known as advanced lipoprotein testing methods (ALT), have gained acceptance in the field of CVD risk assessment and have proven their clinical relevance. In the context of worldwide standardization and harmonization of biological assays, efforts have been initiated toward standardization of ALT methods. However, the complexity of lipoprotein particles and the multiple approaches and methodologies reported to quantify them have rendered these initiatives a critical issue. In this context and to better understand these challenges, this review presents a summary of the major methods available for ALT with the aim to point out the major differences in terms of procedures and quantities actually measured and to discuss the resulting comparability issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A major impediment to LDLP testing is its limited availability in the clinical laboratories, higher cost, and lack of standardization [63], although it does provide additional information on other lipoproteins VLDL and HDL, beyond LDLP.”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,760
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Electrophoretic separation of plasma lipoproteins in agarose gel
Noble, R. P. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42680-x · Cited by 1,307
Gardner, C. D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110029028 · Cited by 843
Research works printed but not linked: 103
- 2010, Ion mobility analysis of lipoproteins
- 1999, Analysis of apolipoproteins and lipoproteins by capillary electrophoresis, Electrophoresis, 2, 2118
- 2000, Handbook of lipoprotein testing, 1
- 2014, Development and evaluation of a novel advanced lipoprotein test based on 2D diffusion ordered 1H-NMR spectroscopy [thesis]
- 2000, Handbook of lipoprotein testing, 625
- 1992, Analysis for cholesterol in all lipoprotein classes by single vertical ultracentrifugation of fingerstick blood and controlled-dispersion flow analysis, Clin Chem, 38, 1898, 10.1093/clinchem/38.9.1898 · DOI
- 1955, The distribution and chemical composition of Ultracentrifugally separated lipoproteins in human serum, J Clin Invest, 34, 1345, 10.1172/JCI103182 · DOI · Paper page
- 2014, Accurate serum apolipoprotein A-I and B measurement using the agilent 1290 infinity LC and 6490 triple quadrupole LC/MS system, Agilent Application Note, 1
- 2014, Development and evaluation of a novel advanced lipoprotein test based on 2D diffusion ordered 1H-NMR spectroscopy [thesis]
- 2000, Handbook of lipoprotein testing, 625
- 1994, Effects of orientational order and particle size on the NMR line positions of lipoproteins, Phys Rev Lett, 72, 4049, 10.1103/PhysRevLett.72.4049 · DOI
- 2012, Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure?, J Am Coll Cardiol, 60, 2616, 10.1016/j.jacc.2012.06.065 · DOI
- 2000, Handbook of Lipoprotein Testing, 609
- 1991, An ultrafine aerosol condensation nucleus counter, Aerosol Sci Technol, 14, 48, 10.1080/02786829108959470 · DOI · Paper page
- 2008, Apo B measurement system and method. WO 2008130686 A1
- 2017, Biomarkers for cardiovascular screening: progress or passé?, Clin Chem, 63, 248, 10.1373/clinchem.2016.254854 · DOI
- 1996, Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women, J Am Med Assoc, 276, 875, 10.1001/jama.1996.03540110029028 · DOI · Paper page
- 2009, Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices, Clin Chem, 55, 407, 10.1373/clinchem.2008.118356 · DOI · Paper page
- 2015, Method for analyzing lipoproteins
- 2000, Handbook of lipoprotein testing, 287
- 2011, Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists, J Clin Lipidol, 5, 338, 10.1016/j.jacl.2011.07.005 · DOI · Paper page
- 2012, Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy, Anal Bioanal Chem, 402, 2407, 10.1007/s00216-011-5705-9 · DOI
- 2015, Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis, Atherosclerosis, 242, 496, 10.1016/j.atherosclerosis.2015.08.021 · DOI · Paper page
- 2010, The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum, Rapid Commun Mass Spectrom, 21, 2585
- 1991, Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy, Clin Chem, 37, 377, 10.1093/clinchem/37.3.377 · DOI · Paper page
- 2000, Handbook of lipoprotein testing, 593
- 1995, Advances in agarose gel electrophoresis of serum lipoproteins, J Chromatogr A, 698, 333, 10.1016/0021-9673(94)01192-H · DOI
- 1995, Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology, J Lipid Res, 36, 2291, 10.1016/S0022-2275(20)39710-8 · DOI
- 2015, Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: does size matter?, Atherosclerosis, 242, 399, 10.1016/j.atherosclerosis.2015.07.040 · DOI
- 2006, Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics, Clin Chem, 52, 1722, 10.1373/clinchem.2005.059949 · DOI
- 2012, Electrospray-differential mobility analysis of bionanoparticles, Trends Biotechnol, 30, 291, 10.1016/j.tibtech.2012.02.003 · DOI
- 2006, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy, Clin Lab Med, 26, 847, 10.1016/j.cll.2006.07.006 · DOI · Paper page
- 2014, Advanced lipoprotein testing: strengths and limitations [Internet]
- 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 · DOI · Paper page
- 2010, Ion mobility analysis of lipoproteins
- 2015, Method for the characterization of lipoproteins. WO 2015 079000 A1
- 2008, Apo B measurement system and method. WO 2008130686 A1
- 1989, Measurement of proteins with the Behring nephelometer – a multicentre evaluation, Clin Chem Lab Med, 27, 261
- 2000, Handbook of lipoprotein testing, 287
- 2015, Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy, J Lipid Res, 56, 737, 10.1194/jlr.D050120 · DOI · Paper page
- 1992, International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials, Clin Chem, 38, 658, 10.1093/clinchem/38.5.658 · DOI
- 1986, High-performance liquid chromatography of serum lipoproteins, Methods Enzymol, 129, 57, 10.1016/0076-6879(86)29062-X · DOI
- 1995, Isotope dilution mass spectrometry as a candidate definitive method for determining total glycerides and triglycerides in serum, Clin Chem, 41, 397, 10.1093/clinchem/41.3.397 · DOI
- 2011, A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk, Circ Cardiovasc Qual Outcomes, 4, 337, 10.1161/CIRCOUTCOMES.110.959247 · DOI · Paper page
- 2000, Handbook of lipoprotein testing, 1
- 2011, Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial), Am J Cardiol, 108, 40, 10.1016/j.amjcard.2011.03.003 · DOI · Paper page
- 2014, NMR measurement of LDL particle number using the Vantera clinical analyzer, Clin Biochem, 47, 203, 10.1016/j.clinbiochem.2014.07.015 · DOI · Paper page
- 1980, Rapid analysis of cholesterol of high density lipoprotein and low density lipoprotein in human serum by high performance liquid chromatography, J Biochem, 87, 1863, 10.1093/oxfordjournals.jbchem.a132933 · DOI
- 2011, Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple-reaction-monitoring mass spectrometry, Clin Chem, 56, 1804
- 2013, Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P?, Clin Chem, 59, 723, 10.1373/clinchem.2013.203208 · DOI
- 2016, Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays, Clin Chem, 62, 48, 10.1373/clinchem.2015.250563 · DOI · Paper page
- 2012, Small dense LDL: an emerging risk factor for cardiovascular disease, Clin Chim Acta, 414, 215, 10.1016/j.cca.2012.09.010 · DOI · Paper page
- 2000, A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples, J Lipid Res, 41, 1020, 10.1016/S0022-2275(20)32045-9 · DOI
- 2016, Recent advances in analytical methods on lipoprotein subclasses: calculation of particle numbers from lipid levels by gel permeation HPLC using “spherical particle model”, J Oleo Sci, 65, 265, 10.5650/jos.ess16020 · DOI
- 2000, Handbook of Lipoprotein Testing, 609
- 1993, Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins, Clin Chem, 39, 2276, 10.1093/clinchem/39.11.2276 · DOI
- 2001, Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix lipoprint LDL system, Clin Chem, 47, 266, 10.1093/clinchem/47.2.266 · DOI · Paper page
- 2000, Assessment of between-instrument variations in a HPLC method for serum lipoproteins and its traceability to reference methods for total cholesterol and HDL-cholesterol, Clin Chem, 46, 63, 10.1093/clinchem/46.1.63 · DOI
- 2011, Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data for the characterisation of human plasma lipoproteins, Metabolomics, 7, 572, 10.1007/s11306-011-0273-8 · DOI
- 1986, Single vertical spin density gradient ultracentrifugation, Methods Enzymol, 128, 181, 10.1016/0076-6879(86)28068-4 · DOI · Paper page
- 2002, Reference materials for the standardization of the apolipoproteins A-I and B and lipoprotein(a) [Internet], e-Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 13
- 2013, Size characterization of airborne SiO2 nanoparticles with on-line and off-line measurement techniques: an interlaboratory comparison study, J Nanoparticle Res, 15, 1919, 10.1007/s11051-013-1919-4 · DOI
- 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk, Circulation, 82, 495, 10.1161/01.CIR.82.2.495 · DOI · Paper page
- 2014, Advanced lipoprotein testing: strengths and limitations [Internet]
- 2011, Lipoprint adequately estimates LDL size distribution, but not absolute size, versus polyacrylamide gradient gel electrophoresis, Lipids, 46, 1163, 10.1007/s11745-011-3611-8 · DOI
- 2015, Method for the characterization of lipoproteins. WO 2015 079000 A1
- 2014, Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin), Circulation, 129, 635, 10.1161/CIRCULATIONAHA.113.004406 · DOI · Paper page
- 2000, Handbook of lipoprotein testing, 593
- 2014, Accurate serum apolipoprotein A-I and B measurement using the agilent 1290 infinity LC and 6490 triple quadrupole LC/MS system, Agilent Application Note, 1
- 1998, Analysis of biomolecules using electrospray and nanoparticle methods: the gas-phase electrophoretic mobility molecular analyzer (GEMMA), J Aerosol Sci, 29, 537, 10.1016/S0021-8502(97)00462-X · DOI
- 2015, Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the JUPITER Trial, Circulation, 132, 2220, 10.1161/CIRCULATIONAHA.115.016857 · DOI · Paper page
- 2002, Reference materials for the standardization of the apolipoproteins A-I and B and lipoprotein(a) [Internet], e-Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 13
- 1969, Comparison of lipoprotein analysis by agarose gel and paper electrophoresis with analytical ultracentrifugation, Lipids, 4, 55, 10.1007/BF02531795 · DOI
- 1999, Analysis of apolipoproteins and lipoproteins by capillary electrophoresis, Electrophoresis, 2, 2118
- 2012, Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the treating to new targets (TNT) study, Circulation, 125, 1979, 10.1161/CIRCULATIONAHA.111.088591 · DOI · Paper page
- 1981, High-resolution plasma-lipoprotein cholesterol profiles by a rapid, high volume semi-automated method, J Lipid Res, 22, 1003, 10.1016/S0022-2275(20)37338-7 · DOI
- 1995, Chromatographic techniques for the isolation and purification of lipoproteins, J Chromatogr B Biomed Appl, 671, 237, 10.1016/0378-4347(95)00051-J · DOI
- 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk, Arterioscler Thromb Vasc Biol, 29, 1975, 10.1161/ATVBAHA.109.190405 · DOI · Paper page
- 2000, Handbook of lipoprotein testing, 647
- 2012, What is the role of advanced lipoprotein analysis in practice?, J Am Coll Cardiol, 60, 2607, 10.1016/j.jacc.2012.04.067 · DOI
- 2014, Quantification of HDL particle concentration by calibrated ion mobility analysis, Clin Chem, 60, 1393, 10.1373/clinchem.2014.228114 · DOI
- 1982, Computerized rapid high resolution quantitative analysis of plasma lipoproteins based upon single vertical spin centrifugation, J Lipid Res, 23, 923, 10.1016/S0022-2275(20)38096-2 · DOI
- 1989, Evaluation of a monoclonal antibody-based enzyme-linked immunosorbent assay as a candidate reference method for the measurement of apolipoprotein B-100, J Lipid Res, 30, 1445, 10.1016/S0022-2275(20)38265-1 · DOI
- 1990, Automated gel permeation chromatography of plasma lipoproteins by preparative fast protein liquid chromatography, J Chromatogr B Biomed Appl, 525, 433, 10.1016/S0378-4347(00)83420-9 · DOI
- 2013, LipoSEARCH ® Analytical GP-HPLC method for lipoprotein profiling and its applications, J Biol Macromol, 13, 21, 10.14533/jbm.13.21 · DOI
- 1997, Analytical capillary isotachophoresis of human serum lipoproteins, Electrophoresis, 18, 1807, 10.1002/elps.1150181015 · DOI
- 2010, Lipoprotein particle profiles by NMR compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119, 931
- 1996, Isotope-dilution mass spectrometric quantification of specific proteins: model application with apolipoprotein A-1, Clin Chem, 42, 1676, 10.1093/clinchem/42.10.1676 · DOI · Paper page
- 1990, Immunological assays of apolipoproteins in plasma: methods and instrumentation, Clin Chem, 36, 591, 10.1093/clinchem/36.4.591 · DOI
- 2015, Method for analyzing lipoproteins
- 2014, 2013 ACC/AHA Guideline on the assessment of cardiovascular risk – a report of the American College of Cardiology/American Heart Association task force on practice guidelines, J Am Coll Cardiol, 63, 2935
- 1994, Quantification of cholesterol in all lipoprotein classes by the VAP-II method, J Lipid Res, 35, 159, 10.1016/S0022-2275(20)40123-3 · DOI
- 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis, 192, 211, 10.1016/j.atherosclerosis.2006.05.007 · DOI · Paper page
- 2006, Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies, J Intern Med, 259, 481, 10.1111/j.1365-2796.2006.01644.x · DOI · Paper page
- 2000, Handbook of lipoprotein testing, 647
- 1968, Electrophoretic separation of plasma lipoproteins in agarose gel, J Lipid Res, 9, 693, 10.1016/S0022-2275(20)42680-X · DOI · Paper page
- 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4 · DOI · Paper page
- 2017, On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins, J Proteomics, 150, 258, 10.1016/j.jprot.2016.09.011 · DOI · Paper page
- 1981, High performance aqueous gel permeation chromatography of serum lipoproteins: selective detection of cholesterol by enzymatic reaction, J Chromatogr – Biomed Appl, 223, 285, 10.1016/S0378-4347(00)80100-0 · DOI
- 2017, Absolute quantification of bio-nanoparticles by electrospray differential mobility analysis: an application to lipoprotein particle concentration measurements, Anal Chem, 89, 2242, 10.1021/acs.analchem.6b02909 · DOI
- 2006, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation, 113, 1556, 10.1161/CIRCULATIONAHA.105.565135 · DOI · Paper page
- 2013, Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC lipoprotein and vascular diseases division working group on best practices, Clin Chem, 59, 752, 10.1373/clinchem.2012.196733 · DOI · Paper page
- 2008, Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis, Clin Chem, 54, 1307, 10.1373/clinchem.2007.100586 · DOI · Paper page
Cited by
Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287037 · Cited by 260
“Therefore, standardization of NMR spectral analysis is urgently needed, as well as harmonization to a unique reference material to allow comparability of NMR data with other subfractionation techniques (72).”
MethodNordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.005 · Cited by 246
“A major impediment to LDLP testing is its limited availability in the clinical laboratories, higher cost, and lack of standardization [63], although it does provide additional information on other lipoproteins VLDL and HDL, beyond LDLP.”
BackgroundNMR and Metabolomics—A Roadmap for the Future
Wishart, D. S., Cheng, L. L., Copié, V., Edison, A. S., Eghbalnia, H. R., Hoch, J. C., Gouveia, G. J., Pathmasiri, W., Powers, R., Schock, T. B., et al. (2022) · Metabolites · doi:10.3390/metabo12080678 · Cited by 215
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1253 · Cited by 211
“This underscores the need to standardize and validate advanced lipoprotein tests, such as NMR- or ion mobility-based LDLP and VLDL particle numbers and size [62, 63], and multiplexed LC-MSMS apolipoprotein profiles [68], which have the potential to become widely available medical tests [99].”
BackgroundWilson, P. W. F., Jacobson, T. A., Martin, S. S., Jackson, E. J., Le, N., Davidson, M. H., Vesper, H. W., Frikke‐Schmidt, R., Ballantyne, C. M., & Remaley, A. T. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.046 · Cited by 141
Metadata
- Authors
- Clouet-Foraison, N., Gaie-Levrel, F., Gillery, P., & Delatour, V.
- Affiliations
- Laboratoire National de Métrologie et d'Essais (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Delatour, Vincent
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2017-01-01
- Volume
- 55
- Issue
- 10
- Pages
- 1453-1464
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2613798300
- Cited by
- 30
- References
- 81
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 5 · 2019: 1 · 2018: 4 · 2017: 3
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Chemistry and Laboratory Medicine (CCLM) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Keywords
- cardiovascular disease risk assessment, cardiovascular biomarkers, lipoprotein quantification, method standardization, assay comparability, lipoprotein particles
- MeSH terms
- Cardiovascular Diseases, Chromatography, High Pressure Liquid, Electrophoresis, Polyacrylamide Gel, Humans, Immunoassay, Lipoproteins, Magnetic Resonance Spectroscopy, Mass Spectrometry, Biomarkers, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling. https://app.cochat.ai/papers/10.1515/cclm-2017-0091
- The paper
- Clouet-Foraison, N., Gaie-Levrel, F., Gillery, P., & Delatour, V. (2017). Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2017-0091
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.